Palladiem’s AbbVie ABBV Stock Holding History

Palladiem’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$832	Hold	4	–	–	﹤0.01%	152
2025 Q4	$914	Buy	+4	New	+$911	﹤0.01%	159

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Palladiem's ABBV Position: Q1 2026 in Review

Palladiem held its AbbVie (ABBV) position steady in Q1 2026 at 4 shares worth $832. The position accounts for ﹤0.01% of the portfolio, ranked #152.

Palladiem first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. The position peaked at $914 in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Palladiem held 4 shares of AbbVie worth $832 as of Q1 2026.
Palladiem left its AbbVie share count unchanged in Q1 2026.
AbbVie made up ﹤0.01% of Palladiem's portfolio in Q1 2026, its #152 holding.
Palladiem first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
Palladiem's AbbVie position peaked at $914 in Q4 2025.
4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Palladiem's 13F filing for Q1 2026, filed 6 May 2026.